Celestica (CLS)
(Delayed Data from NYSE)
$63.06 USD
+1.81 (2.96%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.25 +0.19 (0.30%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.06 USD
+1.81 (2.96%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.25 +0.19 (0.30%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Zacks News
Top Ranked Growth Stocks to Buy for July 30th
by Zacks Equity Research
DOW, CLS, HRI, and TTE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 30, 2021.
Despite Fast-paced Momentum, Celestica (CLS) Is Still a Bargain Stock
by Zacks Equity Research
Celestica (CLS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Celestica (CLS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Celestica (CLS) delivered earnings and revenue surprises of 20.00% and 3.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Celestica (CLS) Reports Next Week: What Awaits?
by Zacks Equity Research
Celestica (CLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celestica (CLS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Celestica (CLS) delivered earnings and revenue surprises of 4.76% and 0.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Celestica (CLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Celestica (CLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Celestica (CLS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Celestica (CLS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PagerDuty (PD) Q4 Loss Narrower Than Expected, Revenues Rise
by Zacks Equity Research
PagerDuty's (PD) fourth-quarter fiscal 2021 results reflect an expanded partner base and new customer wins.
Plexus (PLXS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Plexus (PLXS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Jabil (JBL) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Jabil's (JBL) second-quarter fiscal 2021 results reflect benefits from contract wins in healthcare, automotive, connected devices, cloud and 5G. Steady revenue growth in the DMS segment is observed.
Is Celestica (CLS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Celestica (CLS) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Celestica (CLS) has been struggling lately, but the selling pressure may be coming to an end soon
Plexus (PLXS) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Plexus (PLXS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Investors Undervaluing Celestica (CLS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Growth Stocks to Buy for February 18th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 18th
5 Low Price-to-Book Stocks for Value Investors
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Should Value Investors Consider Celestica (CLS) Stock Now?
by Zacks Equity Research
Let's see if Celestica (CLS) stock is a good choice for value-oriented investors right now from multiple angles.
Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals
Pick These 4 Low P/CF Stocks for a Value-Based Portfolio
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuticals (ALXN) boast low P/CF ratio.
Top Ranked Growth Stocks to Buy for February 12th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 12th
Top Ranked Growth Stocks to Buy for February 9th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 9th
Top Ranked Growth Stocks to Buy for February 5th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 5th
Are Investors Undervaluing Celestica (CLS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Celestica (CLS) Q4 Earnings Top Estimates
by Zacks Equity Research
Celestica (CLS) delivered earnings and revenue surprises of 4.00% and -1.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?